Streetbeat News

Analyst Ratings

FUN

Macquarie analyst Paul Golding maintains an Outperform rating on Cedar Fair (NYSE:FUN) but lowers the price target from $52 to $50.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 3:40 pm

CVAC

B of A Securities analyst Geoff Meacham maintains an 'Underperform' rating on CureVac (NASDAQ:CVAC) and has lowered the price target from $10 to $8.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 3:38 pm

EL

DA Davidson analyst Linda Bolton Weiser maintains a 'Buy' rating on Estee Lauder Cos (NYSE:EL) but lowers the price target from $214 to $185.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 3:36 pm

RVLP

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on RVL Pharmaceuticals (NASDAQ:RVLP) but lowers the price target from $4 to $3.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 3:35 pm

DE

Deutsche Bank analyst Nicole Deblase has maintained a 'Hold' rating on Deere (NYSE:DE) and raised the price target from $398 to $407.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 3:35 pm

ACCO

Barrington Research analyst Kevin Steinke has reiterated an 'Outperform' rating on ACCO Brands (NYSE:ACCO) and maintained a price target of $8.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 3:34 pm

SJM

Deutsche Bank analyst Steve Powers maintains a 'Hold' rating on JM Smucker (NYSE:SJM) and raises the price target from $152 to $153.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 3:28 pm

GEVO

Northland Capital Markets analyst Abhishek Sinha has initiated coverage on Gevo (NASDAQ:GEVO) with a Market Perform rating and a price target of $2.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 3:27 pm

RANI

B of A Securities analyst Geoff Meacham maintains a Buy rating on Rani Therapeutics Hldgs (NASDAQ:RANI) but lowers the price target from $19 to $17.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 3:26 pm

REGN

Canaccord Genuity analyst John Newman has upgraded Regeneron Pharmaceuticals from Hold to Buy and raised the price target from $720 to $992.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 3:26 pm